Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5307753 | 1.00 | SLC6A3 (0.80) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6574453 | 1.00 | SLC6A3 (0.80) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL3000484 | 1.00 | SLC6A3 (0.80) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7347413 | 1.00 | SLC6A3 (0.80) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5731609 | 1.00 | SLC6A3 (0.80) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5731604 | 1.00 | SLC6A3 (0.80) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL3000482 | 1.00 | SLC6A3 (0.80) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6574450 | 1.00 | SLC6A3 (0.80) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5731428 | 0.89 | SLC6A3 (0.76) | SLC6A3 | |
| SCHEMBL5731247 | 0.87 | SLC6A3 (0.82) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106643-A1 | Tropane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2004-06-03 | — | — | US | disclosed |
| EP-1397358-A1 | TROPANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002102801-A1 | TROPANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106643-A1 | Tropane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | SLC6A3 4/4885SLC6A2 2/4885SLC6A4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.